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The nucleoside reverse transcriptase inhibitor (NRTI) 4'-ethynyl-2-fluoro-2'-deoxyadeno-
sine (EFdA) in preclinical development exhibits improved safety and antiviral activity profiles
with minimal drug resistance compared to approved NRTIs. However, the systemic antiviral
efficacy of EFdA has not been fully evaluated. In this study, we utilized bone marrow/liver/
thymus (BLT) humanized mice to investigate the systemic effect of EFdA treatment on HIV
replication and CD4+ T cell depletion in the peripheral blood (PB) and tissues. In particular,
we performed a comprehensive analysis of the female reproductive tract (FRT) and gastro-
intestinal (GI) tract, major sites of transmission, viral replication, and CD4+ T cell depletion
and where some current antiretroviral drugs have a sub-optimal effect.
Results
EFdA treatment resulted in reduction of HIV-RNA in PB to undetectable levels in the major-
ity of treated mice by 3 weeks post-treatment. HIV-RNA levels in cervicovaginal lavage of
EFdA-treated BLT mice also declined to undetectable levels demonstrating strong penetra-
tion of EFdA into the FRT. Our results also demonstrate a strong systemic suppression of
HIV replication in all tissues analyzed. In particular, we observed more than a 2-log differ-
ence in HIV-RNA levels in the GI tract and FRT of EFdA-treated BLT mice compared to
untreated HIV-infected control mice. In addition, HIV-RNA was also significantly lower in the
lymph nodes, liver, lung, spleen of EFdA-treated BLT mice compared to untreated HIV-
infected control mice. Furthermore, EFdA treatment prevented the depletion of CD4+ T
cells in the PB, mucosal tissues and lymphoid tissues.
Conclusion
Our findings indicate that EFdA is highly effective in controlling viral replication and preserv-
ing CD4+ T cells in particular with high efficiency in the GI and FRT tract. Thus, EFdA
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represents a strong potential candidate for further development as a part of antiretroviral
therapy regimens.
Introduction
Current antiretroviral therapy (ART) regimens effectively control peripheral blood (PB)
plasma viral load levels and decrease morbidity and mortality in HIV-infected patients. How-
ever, due to limited penetration of ART, HIV replication can persist in tissue reservoirs such as
the gastrointestinal (GI) tract and female reproductive tract (FRT) and lymphoid tissues [1–3].
Anti-HIV drugs with poor tissue penetrance may also contribute to the development of drug
resistant variants, inflammation, maintenance of viral reservoirs, and HIV transmission [4, 5].
Therefore, new drugs with strong penetration into these tissues are crucial for more effective
HIV treatment, prevention, and eradication/cure strategies.
The nucleoside reverse transcriptase inhibitor (NRTI) 4'-ethynyl-2-fluoro-2'- deoxyadeno-
sine (EFdA), currently in preclinical development, has potent antiviral activity with improved
safety and minimal drug resistance compared to other approved NRTIs [6]. In vitro efficacy
studies have demonstrated that EFdA inhibits HIV-1 replication in primary peripheral blood
mononuclear cells (PBMC) at a 50% effective concentration (EC50) of 50 pM, a potency 4-fold
greater than Tenofovir (TFV) and 400-fold greater than azidothymidine (AZT) [7]. EFdA is
non-toxic in vitro at concentrations as high as 10 μM, with a selectivity index greater than
200,000 [6, 8]. EFdA exhibited increased potency in blocking simian immunodeficiency virus
(SIV) replication in vitro in primary macaque PBMC compared to TFV, AZT and emtricita-
bine (FTC). It also showed efficient inhibition of replication in vivo in two SIV-infected
macaques with advanced acquired immunodeficiency syndrome (AIDS) [9]. In HIV-infected
NOD/SCID Janus kinase 3 knockout mice injected with human PBMC, EFdA treatment
reduced plasma HIV-RNA levels and prevented CD4+ T cell depletion in PB [10]. In addition,
a recent study demonstrated that EFdA decreased HIV replication in vitro in human primary
lymphocytes infected with multiple clade HIV isolates and in plasma of humanized mice
infected with an early passage HIV isolate [11].
Despite these studies, the effect of EFdA on systemic HIV replication, specifically in highly
relevant mucosal tissues where transmission can occur, has not been documented. In the pres-
ent study, we used bone marrow/liver/thymus (BLT) [12–16] humanized mice to analyze the
anti-HIV activity of EFdA in tissues with particular emphasis on the FRT and GI tract. We
administered EFdA (10mg/kg) orally to HIV-infected BLT mice once daily and monitored
HIV-RNA levels in plasma and cervicovaginal lavage (CVL). Following three weeks of EFdA
therapy, HIV-RNA and HIV-DNA in plasma, CVL and multiple tissues including the GI tract
and FRT demonstrated a significantly lower compared to untreated controls. Our findings
indicate that EFdA is a promising antiviral candidate for HIV treatment and prevention
strategies.
Materials and Methods
Generation of BLT humanized mice
BLT mice were prepared as previously described [17, 18]. Briefly, thymus/liver/thymus
implanted NOD/SCIDγc
-/- (NSG; The Jackson Laboratories) were transplanted with autolo-
gous human liver-derived CD34+ hematopoietic stem cells (Advanced Bioscience Resources,
Alameda, CA) and reconstitution of human immune cells in PB was analyzed by flow
EFdA Efficiently Inhibits HIV Replication in GI and FRT of BLT Mice
PLOS ONE | DOI:10.1371/journal.pone.0159517 July 20, 2016 2 / 14
cytometry, as we previously described [19–21]. Mice were maintained under specific-patho-
gen-free conditions by the Division of Laboratory Animal Medicine according to protocols
approved by the Institutional Animal Care and Use Committee at the University of North
Carolina–Chapel Hill.
Virus challenge and administration of EFdA
Stocks of HIV-1JR-CSF were prepared via transient transfection of 293 T cells, and titred using
TZM-bl cells as previously described [22]. HIV-1JR-CSF (30,000 TCIU) was administered intra-
venously by tail vein injection.
EFdA was generously provided by Michael A. Parniak, University of Pittsburgh School of
Medicine. EFdA was reconstituted in phosphate-buffered saline (PBS) at a concentration of 1
mg/mL and administered orally to BLT mice by oral gavage at 10 mg/kg once daily for 3 weeks
beginning at 3 weeks post-HIV infection. PBS (200 μL) was administered by oral gavage to
(untreated) controls.
Specimen collection and processing
PB and CVL samples were collected longitudinally (weekly) pre- and post-HIV exposure for 6
weeks. PB was collected in EDTA and plasma separated for HIV-RNA analysis by centrifuging
for 5 min at 300 g. The remaining blood cells were reconstituted with PBS to restore the origi-
nal volume of the PB sample and used for flow cytometric analysis. Cervicovaginal secretions
(CVS) were obtained by performing a cervicovaginal lavage (CVL, weeks 0–5) with sterile PBS
(3 washes of 20 μl each, ~ 60 μl total volume). To ensure that the procedure was atraumatic,
CVL were performed with 20 μl sterile filter pipette tips that were inserted no more than 1–3
mm into the vaginal cavity. Following centrifugation (300g for 5 min), cell-free supernatants
were used for HIV-RNA analysis. Pellets were re-suspended in PBS and used for flow cyto-
metric analyses. The bone marrow (BM), LN, human thymic organoid (ORG), liver, lung,
spleen, GI tract (from duodenum to rectum) and FRT (vagina, cervix and uterus) were har-
vested at necropsy 6 weeks post-HIV exposure and mononuclear cells were isolated as previ-
ously described [19, 21, 23] for HIV-RNA, HIV-DNA and flow cytometric analyses.
HIV viral load and flow cytometry analysis
PB and CVL HIV-RNA levels were measured using one-step reverse transcriptase real-time
PCR [ABI custom TaqMan Assays-by-Design (limit of detection (LOD): plasma-750 copies/
ml, CVL-1400 copies/60μl) [24, 25]. Plasma and CVL viral load levels below the limit of detec-
tion were plotted as 375 copies/ml and 700 copies/ml respectively. We used these values to cal-
culate means for the groups. The presence of HIV-RNA and HIV-DNA in mononuclear cells
isolated from tissues were determined by real-time RT-PCR (HIV-RNA, LOD-1.5 copies/
105cells and HIV-DNA, LOD of 2.5 copies/105cells) [19, 20]. As a control for the presence of
DNA extracted from human cells, all samples were tested for the presence of human gamma
globin DNA by real-time PCR.
Percentage of CD4+ human T cells were determined by flow cytometry using the following
antibodies directed against human CD4 PerCP (SK3), CD3 PE-Cy7 (SK7), and CD45
APC-Cy7 (2D1) (BD Biosciences). Data was acquired with a BD FACSCanto flow cytometer
and analyzed with BD FACS Diva software (v. 6.1.3) as described previously [26]. Flow cyto-
metric gating for CD4+ T cells was performed first by gating the live cells as determined by for-
ward and side scatter and then on human CD45+ CD3+ T cells. The mean CD45+ events
collected during flow cytometry were 12511 (1380–23881) for PB, 41938 (17058–54998) for
ORG, 25733 (2800–50526) for spleen, 27060 (12103–39353) for lung, 17332 (3628–42965) for
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LN, 58933 (14323–8830) for liver, 21234 (12571–47231) for BM, 723 (368–1851) for GI and
3229 (1473–6202) for FRT. The mean CD3+ events were 10371 (980–21106) for PB, 39725
(17000–51946) for ORG, 19780 (1439–34872) for spleen, 15439 (4724–35362) for lung, 17638
(2639–39823) for LN, 42463 (8349–65526) for liver, 3796 (1474–10294) for BM, 591 (213–
1335) for GI, 1358 (509–3758) for FRT.
Statistical analysis
Repeated measures of two-way ANOVA was used to compare the levels of HIV-RNA in
plasma and CVL between EFdA-treated and untreated mice. A Mann-Whitney test was used
to compare the mean percentage of CD4+ T cells in the PB and CVL, and to compare
HIV-RNA and HIV-DNA levels in the tissues of EFdA-treated and untreated HIV-infected
BLT mice. Wilcoxon matched-pairs signed rank test was used to compare CD4+ T cell levels in
the PB and CVL of BLT mice pre- and post HIV infection. All data is plotted as mean ± S.E.M
and p-values<0.05 were considered significant. All statistical tests were performed using
GraphPad Prism software v6.
Results
Experimental Design
The detailed experimental approach for the experiments described below is depicted in Fig 1.
Humanized BLT mice were constructed and characterized as previously described [19–21].
Twelve BLT mice were infected with HIV-1JR-CSF (30,000 TCIU) intravenously at week 0. Six
BLT mice were included in the EFdA-treated group and 6 mice served as untreated controls.
Beginning at three weeks post-infection, the treatment group was administered EFdA (10mg/
kg) once daily by oral gavage for 3 weeks. PBS was administered by oral gavage to controls
(untreated). PB and CVL were collected from EFdA-treated and untreated mice weekly to mea-
sure viral load levels. Multiple organs (BM, LN, ORG, liver, lung, spleen, GI tract and FRT)
were collected from EFdA-treated and untreated BLT mice at necropsy, 6 weeks post-infection
(3 weeks following EFdA treatment initiation) to quantitate the levels of HIV-RNA,
HIV-DNA, and CD4+ T cells.
Fig 1. Experimental Design.NSGmice were used to construct BLT humanized mice. The peripheral blood (PB) of BLT mice were
monitored longitudinally for human immune reconstitution. BLT mice were infected with HIV-1JR-CSF (30,000 TCIU) intravenously (IV,
day 0). Beginning at 3 weeks post-HIV infection, BLT mice (n = 6) were administered EFdA (10mg/kg) once daily for three weeks via
oral gavage. Control (untreated) mice (n = 6) were administered PBS orally. PB and CVL were collected weekly from EFdA-treated
and untreated mice for the analysis of HIV-RNA and CD4+ T cell levels. EFdA-treated and untreated mice were necropsied at 6
weeks post-infection and tissues harvested for analysis of HIV-RNA, HIV-DNA and CD4+ T cell levels.
doi:10.1371/journal.pone.0159517.g001
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The BLT mice (n = 12) used for these experiments were characterized for human immune
reconstitution in PB prior to HIV infection. Mice were well reconstituted with human hemato-
poietic cells (CD45+, median 73.3%, range 34–91%). The majority of human hematopoietic
cells in PB were human T cells (68.2% range 39–80%). Of the human T cells present, 79.5%
(range 65–95%) were CD4+ T cells (Table 1).
EFdA therapy efficiently reduces plasma HIV-RNA levels
To determine the systemic antiviral effects of EFdA, we longitudinally monitored HIV-RNA
levels in the plasma of EFdA-treated and untreated (Fig 2). At the time of treatment initiation
(week 3 post-infection), mean plasma HIV-RNA levels in the EFdA treatment and control
groups of mice were similar (p = 0.71). Specifically, the mean viral load for mice in the EFdA
treatment and control groups were 1.2 x106 (range 0.3–2.4x106) and 1.4 x106 (range 0.6–
2.6x106) copies per ml plasma respectively. After one week of EFdA treatment, we observed a
dramatic 2-log reduction (mean 1.6x104, range 0.2–3.2x104 copies/ml, p<0.0001) in plasma
HIV-RNA levels in EFdA-treated mice (Fig 2B). No reduction in plasma HIV-RNA levels was
noted in untreated control mice. After three weeks of EFdA treatment, the plasma HIV-RNA
levels in four EFdA-treated mice decreased below LOD. The plasma HIV-RNA levels in the
two EFdA-treated mice with detectable HIV-RNA were reduced by 3-logs to 1074 and 1297
copies/ml after three weeks of EFdA treatment (Fig 2A).
EFdA effectively reduces HIV-RNA and HIV-DNA levels in lymphoid
tissues and effector sites
Several studies have shown high levels of HIV-RNA and HIV-DNA in tissues such as LN,
spleen, liver and lung despite suppressive ART [2–4, 27, 28]. We therefore determined the sys-
temic effect of EFdA on HIV-RNA and HIV-DNA levels in primary and secondary lymphoid
tissues and in effector sites, by comparing the quantities of cell-associated HIV-RNA and
HIV-DNA in tissues of EFdA-treated and untreated HIV-infected BLT mice (Fig 3). Cell-asso-
ciated HIV-RNA levels in the tissues of EFdA-treated BLT mice were significantly lower com-
pared to untreated mice (p = 0.01 for BM, p = 0.002 for ORG, LN, liver, lung, spleen). Notably,
we observed a 3-log difference in the levels of HIV-RNA in the LN of EFdA-treated mice
Table 1. Humanization and HIV-RNA Levels in HIV-infected BLTMice.
BLT Mouse No. Study Group Peripheral blood humanization HIV-RNA levels
%hCD45 %hCD3 %hCD4 Plasma copies/ml (week 6) CVL copies/60μl (week 5)
1 Treated 66.1 80 82 1074 <LOD
2 Treated 67.1 73.6 82.3 1297 <LOD
3 Treated 69.2 70.8 80.4 <LOD <LOD
4 Treated 76.6 68.4 80.4 <LOD <LOD
5 Treated 81.2 62.8 82.2 <LOD <LOD
6 Treated 63.9 38.5 76.1 <LOD <LOD
7 Control 77.6 71.8 78.9 6.3x105 1.4x105
8 Control 86.2 43.1 74.7 14.5x105 0.18x105
9 Control 76.7 68 83.9 1.3x105 3086
10 Control 91.3 67.3 65.4 58x105 9576
11 Control 70.1 39.8 73.1 18x105 9667
12 Control 33.6 77.5 95 17x105 18461
Notes: hCD45- Human CD45, hCD3-Human CD3, hCD4-Human CD4, LOD- limit of detection.
doi:10.1371/journal.pone.0159517.t001
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compared to untreated mice (Fig 3A). EFdA treatment also resulted in significantly lower
HIV-DNA levels in the BM (p = 0.02), LN (p = 0.01), liver (p = 0.002), and lung (p = 0.004) of
EFdA-treated mice compared to untreated mice (Fig 3B). Together, these data indicate that
EFdA effectively controls HIV replication systemically.
CD4+ T cell levels in the PB, lymphoid and effector tissues during EFdA
treatment
Suppression of plasma viremia below detection levels is not often associated with a significant
increase in CD4+ T-cell counts [29]. In this study, we measured CD4+ T cell levels in the PB of
BLT mice prior to HIV infection (week 0), 2 weeks post-HIV infection and during EFdA treat-
ment (3–6 weeks). Three weeks post-HIV infection, CD4+ T cell levels were significantly
decreased in the PB compared to pre-infection levels (mean: %CD4+ T cells weeks 0 vs 3:
76.2% vs 65.5%; p = 0.001). After 3 weeks of treatment, CD4+ T cell levels in the PB of EFdA-
treated mice was significantly higher compared to untreated mice (p = 0.04, Fig 4).
In addition to PB, we also analyzed CD4+ T cell levels in the primary and secondary lym-
phoid tissues and effector tissues after EFdA treatment. We observed significantly higher levels
of CD4+ T cells in the liver (p = 0.04), spleen (p = 0.002) of EFdA-treated mice compared to
untreated mice (Fig 4). The CD4+ T cell levels were also higher in the BM, LN, lung of EFdA-
treated mice compared to untreated mice, however the difference did not reach significance.
Oral administration of EFdA results in a strong reduction in HIV-RNA
levels in CVL and the FRT
In order to establish the effect of EFdA administration on HIV replication in CVL, HIV-RNA
levels in CVL were measured prior to treatment initiation and longitudinally during EFdA
Fig 2. Effect of EFdA administration on the levels of plasma HIV-RNA. A) HIV-RNA levels in the plasma of EFdA-treated (n = 6,
red lines) and untreated (n = 6, blue lines) mice. B) Mean plasma HIV-RNA levels in EFdA-treated (red line) and untreated (blue line)
mice from Panel A. Shaded area indicates the weeks of EFdA (treated) and PBS (untreated controls) administration. Repeated
measures of two-way ANOVA was used to compare the mean levels of HIV-RNA between EFdA-treated and untreated mice.
Horizontal and vertical lines indicate mean and standard error. Dotted lines indicate the limit of detection (750 copies/ml).
doi:10.1371/journal.pone.0159517.g002
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Fig 3. Analysis of HIV-RNA and HIV-DNA levels in lymphoid and effector tissues of EFdA-treated and
untreated HIV-infected BLTmice. A) HIV-RNA and B) HIV-DNA levels in the bone marrow (BM), lymph
node (LN), human thymic organoid (ORG), liver, lung, spleen, of EFdA-treated (n = 6, circles, red) and
untreated (n = 6, square, blue) HIV-infected BLT mice. Dotted lines indicate the limit of detection (HIV-RNA:
1.5 copies/105 cells, HIV-DNA: 2.5 copies/105 cells). Horizontal and vertical lines indicate mean and standard
error. A Mann-Whitney test was used to compare HIV-RNA and HIV-DNA levels between EFdA-treated and
untreated BLT mice (*p<0.05).
doi:10.1371/journal.pone.0159517.g003
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treatment (Fig 5A and 5B). At the time of treatment initiation, CVL HIV-RNA levels were sim-
ilar (p = 0.66) between mice in the treatment (mean: 1.5x105 copies/60μl, range: 0.4–3.8x105
copies/60μl) and control groups (mean: 0.8x105 copies/60μl, range: 0.01–2.5x105 copies/60μl).
Within 2 weeks of EFdA treatment, CVL HIV-RNA levels were reduced to undetectable levels
compared to untreated mice (mean 0.3x105 copies/60μl, range: 0.03–1.4x105 copies/60μl, Fig
5A and 5B). We also measured the levels of HIV-RNA in cells isolated from the FRT after 3
weeks of treatment and we observed more than a 2-log difference (p = 0.002, Fig 5C) in cell-
associated HIV-RNA levels in EFdA-treated mice (mean: 42 copies/105 cells, range: 0.4–102
copies/105 cells) compared to untreated mice (mean: 7849 copies/105 cells, range: 351–30927
copies/105 cells). HIV-DNA levels were also lower in the FRT of EFdA-treated mice compared
to untreated mice however, this difference did not reach statistical significance (Fig 5D). These
findings indicate that EFdA can penetrate into the FRT and efficiently control viral replication.
Fig 4. Effect of EFdA treatment on CD4+ T cell levels in the PB, lymphoid and effector tissues of HIV-
infected BLTMice. Percentage of CD4+ human T cells were measured in the peripheral blood (PB), bone
marrow (BM), lymph node (LN), organoid (ORG), liver, lung and spleen of EFdA-treated (n = 6, red circles) and
untreated (n = 6, blue squares) BLT mice. Horizontal and vertical lines indicate the mean and standard error. A
Mann-Whitney test was used to compare mean CD4+ T cell level between EFdA-treated and untreated mice
(*p<0.05).
doi:10.1371/journal.pone.0159517.g004
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Fig 5. Effect of EFdA administration on HIV-RNA, HIV-DNA and CD4+ T cell levels in FRT and GI tract.
A) HIV-RNA levels in cervicovaginal lavage (CVL) of EFdA-treated (n = 6, red lines) and untreated mice
(n = 6, blue lines). HIV-RNA was not measured in one EFdA-treated mice at 3rd week B) Mean HIV-RNA
levels in CVL of EFdA-treated and untreated mice from panel A. Shaded area indicates the weeks of EFdA
(treated) and PBS (untreated controls) administration. C) HIV-RNA, D) HIV-DNA, and E) Percentage of
CD4+ human T cell levels in the gastrointestinal (GI) and female reproductive tract (FRT), of EFdA-treated
(n = 6, circles, red) and untreated (n = 6, square, blue) HIV-infected BLT mice. Dotted lines indicate the limit of
detection (CVL RNA -1400 copiesl/60μl, cell associated HIV-RNA: 1.5 copies/105 cells, HIV-DNA: 2.5 copies/
105 cells). Horizontal and vertical lines indicate mean and standard error. Repeated measures of two-way
ANOVA was used to compare the mean levels of HIV-RNA in CVL between EFdA-treated and untreated
EFdA Efficiently Inhibits HIV Replication in GI and FRT of BLT Mice
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EFdA efficiently inhibits HIV replication in the GI tract
The GI tract is an important site of HIV transmission and CD4+ T cell depletion particularly
early after infection [30, 31]. In order to investigate the effect of EFdA on viral replication,
mononuclear cells were isolated from GI tract 3 weeks after EFdA treatment as described previ-
ously [23] and cell-associated HIV-RNA and HIV-DNA levels were measured in EFdA-treated
and untreated mice. Over a 2-log difference (p = 0.0002) was noted in the levels of HIV-RNA
in the GI tract of EFdA-treated mice (mean: 3.7 copies/105 cells, range: 2.3–4.3 copies/105 cells,
Fig 5C) compared to untreated mice (mean: 1042 copies/105 cells, range: 24–2933 copies/105
cells). EFdA treatment also resulted in significantly lower levels of HIV-DNA in the GI tract of
EFdA-treated mice (p = 0.04, mean: 728 copies/105 cells, range: 20–1412 copies/105 cells) com-
pared to untreated mice (mean: 4361 copies/105 cells, range: 801–7992 copies/105 cells) (Fig
5D). Together, these results demonstrate the strong ability of EFdA to control HIV replication
in the GI tract.
Effects of EFdA treatment on CD4+ T cell levels in the gastrointestinal
and female reproductive tract
Studies have shown a more pronounced depletion of CD4+ T cells in the GI tract mucosa than
in PB. Examining the restoration and/or maintenance of CD4+ T cells in GI tract provides a
more accurate assessment of the efficacy of ART [32]. Similar to the GI tract, tissues of the FRT
contain partially activated, memory CD4+ T cells that can serve as targets for HIV [33] and
experimental infection of rhesus macaques with SIV has shown a rapid depletion of CD4+ T
cells [34]. In this study, we measured CD4+ T cell levels in CVL of BLT mice prior to HIV
infection (week 0), 3 weeks post-HIV infection and during EFdA treatment (3–6 weeks). Three
weeks post HIV infection, CD4+ T cell levels were significantly decreased in the CVL of BLT
mice (mean: %CD4+ T cells, weeks 0 vs 3: 60.1% vs 5.3%; p = 0.004). Two weeks of EFdA treat-
ment did not result in significant differences in the levels of CVL CD4+ T cells between EFdA-
treated and untreated mice (mean: %CD4+ T cells, EFdA-treated mice: 44.3%; untreated mice:
24%, p = 0.12). However, analysis of FRT tissue after 3 weeks of EFdA treatment showed signif-
icantly higher levels of CD4+ T cells in the EFdA-treated mice compared to untreated mice
(p = 0.01, Fig 5E). The CD4+ T cell levels were also higher in the GI tract of EFdA-treated mice
compared to untreated mice, however the difference did not reach significance (Fig 5E).
Discussion
Efficient treatment of HIV infection with ART can reduce plasma HIV-RNA levels in patients
to below the detection limit of clinical assays (50 copies of HIV-RNA/ml). However, some anti-
retroviral drugs like AZT and lamivudine that are widely used in developing countries have
been shown to have a sub-optimal therapeutic response in the FRT and lymphoid tissues lead-
ing to persistent HIV replication [2, 27, 28]. This can result in the emergence and transmission
of HIV drug resistant variants and chronic inflammation [4, 5]. Therefore, it is imperative to
examine the ability of novel HIV treatment strategies to inhibit HIV replication at these sites.
In the present study, we used humanized BLT mice to evaluate the systemic antiviral efficacy of
EFdA, a novel NRTI, with particular emphasis on the FRT and the GI tract, major sites of HIV
transmission and CD4+ T cell depletion [30, 31, 35].
mice. A Mann-Whitney test was used to compare mean HIV-RNA and HIV-DNA levels and CD4+ T cell levels
between EFdA-treated and untreated BLT mice (*p<0.05).
doi:10.1371/journal.pone.0159517.g005
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Daily oral EFdA treatment of HIVJR-CSF infected BLT mice for 3 weeks resulted in a decline
in plasma HIV-RNA to undetectable levels. Greatly expanding on previous reports [10, 11],
here we demonstrate a strong decline in HIV-RNA in CVL to levels below our limit of detec-
tion (1400 copies/60μl) showing that EFdA can penetrate into and efficiently reduce virus rep-
lication in the FRT. Recently, EFdA has been shown to suppress SIV replication in prostate,
seminal vesicles, and lymphoid tissues of one SIV-infected macaque treated for 4 months [9].
To better characterize the ability of EFdA to suppress HIV replication, we performed compre-
hensive analyses of the levels of HIV-RNA and HIV-DNA in multiple tissues including the
FRT and GI tract of EFdA-treated mice. We observed significantly lower levels of cell-associ-
ated HIV-RNA in the FRT and GI tract of EFdA-treated mice compared to untreated mice.
Furthermore, HIV-DNA levels were lower in the GI tract of EFdA-treated mice compared to
untreated mice. Taken together, our results demonstrate that EFdA efficiently penetrates into
the FRT and GI tract, the major sites of viral replication. These results strongly suggest that
EFdA treatment may also reduce the likelihood of HIV transmission.
There is evidence that the liver, lung, spleen and LN can also serve as possible viral sanctuar-
ies that could further complicate HIV treatment [2, 36]. Hence, we measured HIV-RNA and
HIV-DNA levels in primary and secondary lymphoid tissues and effector sites like the liver
and lung after 3 weeks of EFdA therapy. We observed significantly lower levels of cell-associ-
ated HIV-RNA in primary and secondary lymphoid tissues of EFdA-treated mice compared to
untreated mice. In particular, we observed a 2–3 log difference in cell-associated HIV-RNA in
the spleen and LN of EFdA-treated mice compared to control mice. In addition, HIV-DNA
levels were significantly lower in the BM, LN, ORG, liver and lung. Overall, these findings indi-
cate that EFdA can effectively suppress systemic virus replication including “viral sanctuary”
sites like the LN, GI tract and FRT.
Successful clinical outcomes are dependent on adequate recovery of CD4+ T cells following
ART [37]. There is now increasing evidence to show that patients failing to achieve CD4+ T-
cell counts>500 cells/μl are at increased risk of developing serious non-AIDS events [38],
including cardiovascular disease, hypertension, liver disease, non-AIDS malignancies and neu-
rocognitive impairment [39]. In this study, we measured the efficacy of EFdA treatment to pre-
vent depletion of CD4+ T cells in the PB, CVL and tissues including the FRT, GI tract and
lymphoid tissues. CD4+ T cell levels in CVL dramatically decreased following HIV infection.
After only two weeks of EFdA treatment, we observed a trend towards higher CD4+ T cells in
CVL of EFdA-treated mice. These results are consistent with prior studies describing the rapid
decline of CD4+ T cells in CVL and FRT following HIV exposure in comparison to the more
moderate decline in CD4+ T cell levels in PB. Furthermore, these results are consistent with
previous reports describing the gradual restoration of CD4+ T cells in CVL following the initia-
tion of ART [40]. We observed higher levels of CD4+ T cells in the PB and most importantly in
the GI tract and FRT tissues of EFdA-treated mice after 3 weeks of treatment compared to
untreated mice. Thus, in addition to demonstrating the effectiveness of EFdA in reducing HIV
replication, our study also demonstrates the potential clinical benefit of novel EFdA in CD4+ T
cell recovery.
In summary, EFdA treatment of HIV-infected BLT mice resulted in a significant reduction
in HIV-RNA levels in the PB and CVL to undetectable levels. Importantly, EFdA treatment
resulted in a strong reduction in HIV-RNA levels in both the FRT and GI tract tissues. Our
results show that EFdA is efficient in penetrating into these tissues and effectively suppresses
viral replication. Furthermore, EFdA treatment prevented depletion of CD4+ T cells in the
lymphoid and mucosal tissues demonstrating further potential clinical benefits. These pre-clin-
ical studies strongly suggest that EFdA has outstanding characteristics to serve as an excellent
component of future ART formulations for HIV therapy and prevention.
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